Biggest insider buyers of 2026
The insiders who spent the most buying their own company's shares on the open market in 2026.
Covers 2026; updated October 31, 2026.
| # | Insider | Company | Trades | Value |
|---|---|---|---|---|
| 1 | GATES WILLIAM H III | Republic Services Inc. | 61 | $952,967,174 |
| 2 | Angeliki Frangou | Navios Maritime Partners LP | 101 | $854,436,939 |
| 3 | William A. Ackman | Pershing Square Inc., Pershing Square USA Ltd. | 8 | $259,877,496 |
| 4 | BERTARELLI ERNESTO | Madison Air Solutions Corporation | 1 | $218,999,984 |
| 5 | Warren E. Buffett | Lennar Corporation | 14 | $190,265,378 |
| 6 | John C. Malone | Atlanta Braves Holdings Inc., Liberty Capital Corporation, Liberty Latin America Ltd., Liberty Live Holdings Inc. | 39 | $163,153,235 |
| 7 | Noubar Afeyan | Generate Biomedicines Inc. | 6 | $150,000,000 |
| 8 | Jeffrey Terry Green | The Trade Desk Inc. | 4 | $148,101,266 |
| 9 | Neil Mehta | Coupang Inc. | 3 | $136,566,051 |
| 10 | Andrew T. Kaplan | Kailera Therapeutics Inc. | 1 | $134,375,008 |
| 11 | Ryan Cohen | GameStop Corporation | 9 | $118,561,492 |
| 12 | Milton C. Ault III | Alzamend Neuro Inc., Hyperscale Data Inc., Universal Safety Products Inc. | 120 | $104,622,287 |
| 13 | V. Prem Et Al Watsa | Under Armour Inc. | 14 | $86,426,975 |
| 14 | Keith A. Meister | GeneDx Holdings Corp. | 29 | $74,032,163 |
| 15 | Robert W. Duggan | Pulse Biosciences Inc, Summit Therapeutics Inc. | 3 | $64,447,188 |
| 16 | Rajeev M. Shah | Artiva Biotherapeutics Inc., Hemab Therapeutics Holdings Inc., Mineralys Therapeutics Inc. | 10 | $61,179,782 |
| 17 | Carl L. Gordon | ADARx Pharmaceuticals Inc., BlossomHill Therapeutics Inc., Electra Therapeutics Inc., Scribe Therapeutics Inc. | 7 | $61,149,995 |
| 18 | Tor Olav Troim | Borr Drilling Limited | 13 | $56,536,300 |
| 19 | Meyer Malka | Robinhood Markets Inc. | 3 | $55,306,560 |
| 20 | Mahkam Zanganeh | Summit Therapeutics Inc. | 2 | $51,447,200 |
| 21 | Adam D. Portnoy | Service Properties Trust | 1 | $49,999,999 |
| 22 | Simeon George | ADARx Pharmaceuticals Inc., Avalyn Pharma Inc., Odyssey Therapeutics Inc. | 8 | $47,199,980 |
| 23 | Denise Aguiar Alvarez | Banco Bradesco Sa | 24 | $41,686,694 |
| 24 | Oleg Nodelman | Aktis Oncology Inc. | 2 | $39,999,996 |
| 25 | Dirkson R. Charles | DPC Holdings PLC, Loar Holdings Inc. | 5 | $39,781,608 |
| 26 | Edward Herring | Summit Midstream Corporation | 1 | $37,946,131 |
| 27 | Gregory George | Mesoblast Limited | 30 | $37,532,070 |
| 28 | Bob R. Simpson | TXO Partners L.P. | 21 | $36,591,563 |
| 29 | Andrew Phillips Reed | Figma Inc. | 3 | $36,533,649 |
| 30 | Ernest S. Rady | American Assets Trust Inc. | 45 | $36,131,599 |
| 31 | Erez Chimovits | ADARx Pharmaceuticals Inc., Braveheart Bio Inc. | 3 | $35,965,772 |
| 32 | Chung-Yao Yin | Gogoro Inc. | 2 | $35,114,298 |
| 33 | Julian Baker | Kodiak Sciences Inc | 30 | $34,962,746 |
| 34 | Matthew Wilks | Flotek Industries Inc., ProFrac Holding Corp. | 3 | $34,721,852 |
| 35 | Atlantic GenPar (Lux) SCSp General | Alkami Technology Inc. | 3 | $34,664,924 |
| 36 | Ryan Israel | Pershing Square USA Ltd. | 4 | $34,615,216 |
| 37 | Srinivas Akkaraju | Alumis Inc., Kalaris Therapeutics Inc., Scholar Rock Holding Corporation | 12 | $33,906,406 |
| 38 | Jared Isaacman | Shift4 Payments Inc. | 6 | $33,609,188 |
| 39 | Rubens Aguiar Alvarez | Banco Bradesco Sa | 7 | $32,885,279 |
| 40 | Paul L. Berns | Kardigan Inc., Lyell Immunopharma Inc. | 2 | $32,499,985 |
| 41 | Paul J. Fribourg | International Flavors & Fragrances Inc. | 6 | $31,282,987 |
| 42 | Matthew T. Moroun | Pamt Corp | 1 | $31,242,080 |
| 43 | Atlantic (Lux) S.a R.l. General | Liftoff Mobile Inc. | 1 | $29,999,981 |
| 44 | Anthony Ping Yeow Tan | Grab Holdings Limited | 1 | $29,911,500 |
| 45 | James Monroe III | Globalstar Inc. | 1 | $29,839,232 |
| 46 | Mitchell Jacobson | MSC Industrial Direct Company Inc. | 3 | $28,984,170 |
| 47 | Edward P. Garden | Fortune Brands Innovations Inc. | 4 | $28,653,958 |
| 48 | Ramin Kamfar | Bluerock Homes Trust Inc., Bluerock Private Real Estate Fund | 24 | $28,044,260 |
| 49 | Kevin Tang | Aurinia Pharmaceuticals Inc, Boundless Bio Inc., Fulcrum Therapeutics Inc. | 43 | $27,680,711 |
| 50 | Kenneth S. Courtis | Alpha Metallurgical Resources Inc. | 59 | $25,922,264 |
| 51 | James G. Coulter | Odyssey Therapeutics Inc. | 1 | $25,000,002 |
| 52 | Trygve Seglem | KNOT Offshore Partners LP | 1 | $25,000,000 |
| 53 | Adam Koppel | Kailera Therapeutics Inc. | 1 | $25,000,000 |
| 54 | Stephen G. Pagliuca | Norwegian Cruise Line Holdings Ltd. | 2 | $24,992,300 |
| 55 | Brian Guan-Chyun Liu | CG Oncology Inc. | 1 | $24,814,454 |
| 56 | Richard M. Cashin Jr. | AdaptHealth Corp. | 5 | $24,352,291 |
| 57 | Robert C. Pohlad | PepsiCo Inc. | 4 | $23,686,389 |
| 58 | Robert Nelsen | City Therapeutics Inc., Kardigan Inc. | 2 | $23,060,000 |
| 59 | Mauad Bruno Sousa | Aura Minerals Inc. | 8 | $22,843,570 |
| 60 | Lachlan K. Murdoch | Fox Corporation | 2 | $20,907,781 |
| 61 | James Healy | Rapport Therapeutics Inc. | 4 | $20,359,080 |
| 62 | GADICKE ANSBERT | Aktis Oncology Inc. | 1 | $20,029,986 |
| 63 | Nan (Ln) Li | Odyssey Therapeutics Inc. | 1 | $19,999,998 |
| 64 | Marc L. Andreessen | Braveheart Bio Inc. | 1 | $19,800,000 |
| 65 | Patrick G. Enright | Veradermics Incorporated | 2 | $18,275,000 |
| 66 | Ben Hakim | Pershing Square USA Ltd. | 2 | $17,500,000 |
| 67 | Edward T. Mathers | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 68 | Scott D. Sandell | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 69 | Makhzoumi Mohamad | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 70 | Yang Rick | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 71 | BASKETT FOREST | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 72 | Florence Anthony A. Jr. | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 73 | Walker Paul Edward | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 74 | Carmen Chang | Korro Bio Inc., SpyGlass Pharma Inc. | 2 | $17,300,881 |
| 75 | Scott C. Nuttall | KKR & Co. Inc. | 4 | $17,223,587 |
| 76 | Joseph Y. Bae | KKR & Co. Inc. | 5 | $17,201,530 |
| 77 | Sardar Biglari | Biglari Holdings Inc. | 9 | $17,076,470 |
| 78 | Benjamin A. Horowitz | Navan Inc. | 4 | $16,778,030 |
| 79 | Sprott Eric | Hycroft Mining Holding Corporation | 5 | $15,776,250 |
| 80 | Paul J. Sarvadi | Insperity Inc. | 9 | $15,495,676 |
| 81 | Petros Panagiotis Panagiotidis | AI Okto Corp., Toro Corp. | 10 | $15,310,543 |
| 82 | Peter Yu | Factorial Energy Inc. | 8 | $15,215,504 |
| 83 | WALTERS WILLIAM THURMAN | Zentalis Pharmaceuticals Inc. | 1 | $15,172,500 |
| 84 | Helen Susan Kim | Aktis Oncology Inc. | 2 | $15,030,000 |
| 85 | Hal Barron | Quantinuum Inc. | 1 | $15,000,000 |
| 86 | Diyong Xu | Q32 Bio Inc. | 2 | $15,000,000 |
| 87 | Ali Behbahani | SpyGlass Pharma Inc. | 1 | $15,000,000 |
| 88 | Steven Kenneth Hudson | Pinnacle Acquisition Corporation | 2 | $14,750,000 |
| 89 | Gregg Williams | Vivani Medical Inc. | 11 | $14,649,998 |
| 90 | Marcos Marcelo Mindlin | Pampa Energia S.A. | 9 | $14,527,616 |
| 91 | Michael (Mike) Joseph Quinn | DPC Holdings PLC | 1 | $14,358,993 |
| 92 | Hartley R. Rogers | Hamilton Lane Incorporated | 8 | $12,997,677 |
| 93 | Nicholas Anthony Botta | Pershing Square USA Ltd. | 1 | $12,500,000 |
| 94 | David P. Bonita | Prelude Therapeutics Incorporated | 2 | $12,499,999 |
| 95 | Andrew Kai Kang | RoboStrategy Inc. | 2 | $12,464,988 |
| 96 | Neal C. Bradsher | Insight Molecular Diagnostics Inc., STAAR Surgical Company | 6 | $12,424,139 |
| 97 | Andrew Rechtschaffen | Pinnacle Acquisition Corporation | 2 | $12,250,000 |
| 98 | Dylan G. Haggart | Stride Inc. | 4 | $12,240,310 |
| 99 | Steven B. Klinsky | New Mountain Finance Corporation | 14 | $11,983,539 |
| 100 | Mark T. Bertolini | Oscar Health Inc. | 1 | $11,920,000 |
How this ranking is built
Open-market purchases (transaction code P) reported on SEC Forms 4 and 5 by directors, officers and 10% owners, dated in the year, valued at shares × reported price and summed per insider (by SEC CIK). Individuals only: funds, trusts and holding companies that report as 10% owners are left out, since several of them often report the same shares on one joint filing. Amended filings are not counted; grants, option exercises and awards are left out. Trades whose filed price cannot be right — one line worth over $1 billion, or a price more than 10 times the company's median that year — are left out too: filers sometimes type the total into the price field.
Free to cite with a link to this page. Spotted an error? Tell us.